Compare Abeona Therapeutics Inc (ABEO) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Schwab US Dividend Equity ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Schwab US Dividend Equity ETF trades at $32.34. Which is the better fit depends on your goals.
| ABEO | SCHD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $32.83 |
52-Week Low | $4.17 | $26.38 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SCHD trades at $32.24, down 0.46% today, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's dividend strategy is gaining attention amid rising interest in income-focused investments, with recent articles highlighting its 3.29% yield and low 0.06% expense ratio. Support and resistance levels cluster around $32-$33, indicating potential consolidation near current levels.
SCHD offers exposure to quality dividend-paying US stocks but faces mixed sentiment with some analysts citing underperformance versus broader markets. The fund's defensive positioning provides income stability, though total return comparisons with growth-oriented ETFs remain a key consideration for investors seeking balanced portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
